Published in:
Volume 9 / Year 2020 / Issue 1

Overview of non-innovator biological products in India

Page: 30-6

Abstract: As per regulatory requirements, biosimilar drugs must show high similarity to their reference product in quality, preclinical and clinical tests. It is by these means that biosimilars are considered… Read More »

Go Back Print